The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier ...
Cycling Weekly on MSN
'Don't die of embarrassment': Why men need to check their risk of prostate cancer – and not worry that cycling is a factor
Sir Chris Hoy’s stage-four diagnosis has put prostate cancer under the spotlight among cyclists. Cycling Weekly tackles the ...
Please provide your email address to receive an email when new articles are posted on . A urine-based test helped reduce unnecessary biopsies among men with prostate cancer. The test appeared to be ...
The Advertising Standards Authority (ASA) has prohibited advertisements for prostate supplements and home testing kits, fearing they could mislead vulnerable individuals or deter them from appropriate ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven
Feedback